NACE® is a non-invasive prenatal screening that analises the most frequent chromosomal alterations.
It detects abnormalities in chromosomes such us:
COVERAGE OF THE NACE TEST FOR SINGLE
PREGNANCIES ORDERED BY THEY IMPORTANCE
According to data from the 2012 European Registry for Prenatal
Diagnosis , abnormalities in chromosomes 21, 18, and 13 represent
71% of all chromosomal alterations detected.
* Chui et al., BMJ 2011;342:c7401.
* Wellesley et al.2012: Eur J of Hum Gen. 11 January 2012
*Aneuploidies for sex chromosomes not analyzed. Presence or absence of Y chromosome informed.
*Gregg AR, Skotko BG, Benkendorf JL, et al. : Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18(10):1056–65. 10.1038/gim.2016.97
When only a biochemical screening is performed:
Out of every 20 women who test positive for Down syndrome, only one will be carrying a baby with Down syndrome.
Out of every 20 women carrying a baby with Down syndrome, 3 will test negative by biochemical screening.
Depending on the screening results, diagnostic testing approach should be karyotype and: